ArticleJCEM case reports2026
Transient neonatal hypothyroidism due to maternal seaweed soup ingestion: a report of 3 cases.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seaweed soup (miyeok-guk) is traditionally consumed daily by Korean women during pregnancy and postpartum, often resulting in maternal iodine intake exceeding 2000 µg/day, which can induce neonatal hypothyroidism (NH) in breastfed infants. Neonatal hypothyroidism refers to transient thyroid dysfunction from extrinsic iodine exposure, distinct from congenital hypothyroidism (CH) due to intrinsic thyroid defects. We present 3 infants of Korean descent with NH associated with maternal seaweed soup consumption. Case 1 is a preterm infant with severe hypothyroidism resolving rapidly after maternal discontinuation of seaweed soup, with levothyroxine discontinued at 6 months. Case 2 presented with subclinical hypothyroidism on day of life 11 and an atypical course requiring dose adjustments before proving transient at age 3.5 years. Case 3 had severe hypothyroidism at birth and was treated for 6 years as presumed CH; however, levothyroxine dose remained unchanged despite significant growth, and therapy was discontinued after maternal dietary history was obtained, confirming transient disease. These cases demonstrate that initial thyroid-stimulating hormone severity poorly predicts permanence and that levothyroxine dose trajectory is more reliable. Culturally sensitive history-taking and systematic reevaluation at age 3 can prevent unnecessary lifelong therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.